- Home
- APVO vs BDRX Comparison
APVO vs BDRX Comparison
Compare APVO & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- BDRX
- Stock Information
- Founded
- APVO 2016
- BDRX 2000
- Country
- APVO United States
- BDRX United Kingdom
- Employees
- APVO N/A
- BDRX N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- BDRX Biotechnology: Pharmaceutical Preparations
- Sector
- APVO Health Care
- BDRX Health Care
- Exchange
- APVO Nasdaq
- BDRX Nasdaq
- Market Cap
- APVO 4.1M
- BDRX 4.3M
- IPO Year
- APVO N/A
- BDRX N/A
- Fundamental
- Price
- APVO $1.98
- BDRX $6.60
- Analyst Decision
- APVO Strong Buy
- BDRX
- Analyst Count
- APVO 1
- BDRX 0
- Target Price
- APVO $5,920.00
- BDRX N/A
- AVG Volume (30 Days)
- APVO 122.5K
- BDRX 33.0K
- Earning Date
- APVO 08-11-2025
- BDRX 09-29-2025
- Dividend Yield
- APVO N/A
- BDRX N/A
- EPS Growth
- APVO N/A
- BDRX N/A
- EPS
- APVO N/A
- BDRX N/A
- Revenue
- APVO N/A
- BDRX N/A
- Revenue This Year
- APVO N/A
- BDRX N/A
- Revenue Next Year
- APVO N/A
- BDRX N/A
- P/E Ratio
- APVO N/A
- BDRX N/A
- Revenue Growth
- APVO N/A
- BDRX N/A
- 52 Week Low
- APVO $1.72
- BDRX $5.85
- 52 Week High
- APVO $381.10
- BDRX $160.00
- Technical
- Relative Strength Index (RSI)
- APVO 32.74
- BDRX 36.03
- Support Level
- APVO $1.87
- BDRX $6.31
- Resistance Level
- APVO $2.07
- BDRX $7.24
- Average True Range (ATR)
- APVO 0.18
- BDRX 0.39
- MACD
- APVO 0.04
- BDRX 0.04
- Stochastic Oscillator
- APVO 29.55
- BDRX 30.85
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.